Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe

• DOI: 10.1016/j.esmoop.2023.101628
• Publication Date: 2023-09-14T03:40:13Z
• Authors: P. Hofman; F. Calabrese; I. Kern; J. Adam; A. Alarcão; I. Alborelli; N.T. Anton; A. Arndt; A. Avdalyan; M. Barberis; H. Bégueret; B. Bisig; H. Blons; P. Boström; L. Brcic; G. Bubanovic; A. Buisson; A. Caliò; M. Cannone; L. Carvalho; C. Caumont; A. Cayre; L. Chalabreysse; M.P. Chenard; E. Conde; M.C. Copin; J.F. Côté; N. D’Haene; H.Y. Dai; L. de Leval; P. Delongova; M. Denčić-Fekete; A. Fabre; F. Ferenc; F. Forest; F. de Fraipont; M. Garcia-Martos; G. Gauchotte; R. Geraghty; E. Guerin; D. Guerrero; S. Hernandez; P. Hurník; B. Jean-Jacques; K. Kashofer; D. Kazdal; S. Lantuejoul; C. Leonce; A. Lupo; U. Malapelle; R. Matej; J.L. Merlin; K.D. Mertz; A. Morel; A. Mutka; N. Normanno; P. Ovidiu; A. Panizo; M.G. Papotti; E. Parobkova; G. Pasello; P. Pauwels; G. Pelosi; F. Penault-Llorca; T. Picot; N. Piton; A. Pittaro; G. Planchard; N. Poté; T. Radonic; I. Rapa; A. Rappa; C. Roma; M. Rot; J.C. Sabourin; I. Salmon; S. Savic Prince; A. Scarpa; E. Schuuring; I. Serre; V. Siozopoulou; D. Sizaret; S. Smojver-Ježek; J. Solassol; K. Steinestel; J. Stojšić; C. Syrykh; S. Timofeev; G. Troncone; A. Uguen; S. Valmary-Degano; A. Vigier; M. Volante; S.G.F. Wahl; A. Stenzinger; M. Ilié
• Keywords: Turnaround time

Testing for epidermal growth factor receptor (EGFR) mutations is an essential recommendation in guidelines metastatic non-squamous non-small-cell lung cancer, and considered mandatory European countries. However, practice, challenges are often faced when carrying out routine biomarker testing, including access to inadequate tissue samples long turnaround times (TATs).To evaluate the real-world EGFR testing practices of pathology laboratories, online survey was set up validated by Pulmonary Pathology Working Group Society distributed 64 expert laboratories. The retrospective focussed on laboratory organisation daily practice pathologists molecular biologists between 2018 2021.TATs varied greatly both within These discrepancies may be partly due reflex practices, as 20.8% laboratories carried only at request clinician. Many across Europe still favour single-test sequencing a primary method mutation identification; 32.7% indicated that they used targeted techniques 45.1% single-gene followed next-generation (NGS), depending case. Reported rates were consistent over time with no significant decrease number tests 2020, despite increased pressure facilities during COVID-19 pandemic. ISO 15189 accreditation reported 42.0% biology sequencing, 42.3% NGS. 92.5% regularly participate external quality assessment scheme.These results highlight strong heterogeneity occurs thoracic Europe. Even among there variability capabilities, TAT, accreditation, stressing need harmonise reimbursement technologies decision-making algorithms